Health Care Select SPDR (XLV) Intel
US Healthcare & Pharma • Sectors & Real Assets
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more....
Are Wall Street Analysts Bullish on Cardinal Health Stock?
As Cardinal Health has outpaced relative to the broader market over the past year, Wall Street analysts maintain a strongly optimistic outlook about the stock’s prospects....
STAT+: Pharmalittle: We’re reading about Replimune’s melanoma drug, a Medicare policy change, and more
Eli Lilly and Novo Nordisk convinced a federal judge to toss an antitrust lawsuit by a compound pharmacy...
STAT+: He grew up near Boston, went to Harvard, and worked at MIT. Why did he found his startup in California?
Boston, with its rising costs, high taxes, and business climate, is losing ground to rivals across the country, sometimes even in biotech....
Meta ordered to pay $567 million in New Mexico for teen mental health fund
News insight provided by Reuters.
Veteran manager buys 2 ETFs as market shifts
News insight provided by thestreet.com.
STAT+: FDA approves Replimune melanoma drug previously rejected twice
The FDA approved Replimune’s treatment for advanced melanoma, dealing the company and patient advocates a big win after a tumultuous saga....
STAT+: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts
A little-noticed government policy shift caused a seven-year delay in choosing a costly medicine for Medicare price negotiations, an advocacy group says....
STAT+: Study reveals new role for tau, a top target for Alzheimer’s drug development
The protein tau is top target for Alzheimer’s drug development, and a new study bolsters those efforts by describing a previously unknown role that tau plays in neurodegeneration....
STAT+: Two FDA approvals — a new drug and a new vaccine
Takeda's narcolepsy drug approved, the first mRNA flu shot approved, and more biotech updates from The Readout...
KeyBanc to restructure $600M behavioral health deal that failed to clear market despite 8% yield
News insight provided by Bond Buyer.
STAT+: Pharmalittle: We’re reading about Moderna’s flu shot, a death in a gene-editing trial in China, and more
In today's Pharmalittle newsletter: Moderna's mRNA flu shot approved, a death reported in a gene-editing trial in China, and more....
STAT+: Biotech’s next big bet: A Tenax study of a heart failure treatment
Tenax Therapeutics will soon report results from a Phase 3 study that is one of the biggest binary biotech stock events remaining in the sector this year....
STAT+: A scientist-turned-biotech executive is notching some wins, and enjoying it
Scientist-turned-biotech executive Greg Verdine is having a very good year....
Compiling Intel...